Compare Stocks: DYN, BMRN, IBRX, and KRYS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$54.79 -0.2%	$63.62	$49.26 ▼ $70.98	$10.63B	0.22	2.19 million shs	2.15 million shs
DYN Dyne Therapeutics	$16.64 +1.6%	$21.56	$13.73 ▼ $27.31	$3.06B	1.12	3.33 million shs	3.57 million shs
IBRX ImmunityBio	$10.51 +6.1%	$8.31	$1.95 ▼ $12.43	$10.50B	0.02	14.26 million shs	18.60 million shs
KRYS Krystal Biotech	$331.61 +1.3%	$340.04	$179.19 ▼ $382.54	$9.69B	0.5	306,995 shs	196,948 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-0.18%	-4.18%	-14.94%	-7.32%	+0.18%
DYN Dyne Therapeutics	+1.65%	+9.47%	-13.29%	-28.95%	+14.29%
IBRX ImmunityBio	+6.05%	+2.24%	+30.40%	+27.86%	+315.42%
KRYS Krystal Biotech	+1.32%	+2.89%	-4.73%	-9.35%	+77.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$54.79 -0.2%	$63.62	$49.26 ▼ $70.98	$10.63B	0.22	2.19 million shs	2.15 million shs
DYN Dyne Therapeutics	$16.64 +1.6%	$21.56	$13.73 ▼ $27.31	$3.06B	1.12	3.33 million shs	3.57 million shs
IBRX ImmunityBio	$10.51 +6.1%	$8.31	$1.95 ▼ $12.43	$10.50B	0.02	14.26 million shs	18.60 million shs
KRYS Krystal Biotech	$331.61 +1.3%	$340.04	$179.19 ▼ $382.54	$9.69B	0.5	306,995 shs	196,948 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-0.18%	-4.18%	-14.94%	-7.32%	+0.18%
DYN Dyne Therapeutics	+1.65%	+9.47%	-13.29%	-28.95%	+14.29%
IBRX ImmunityBio	+6.05%	+2.24%	+30.40%	+27.86%	+315.42%
KRYS Krystal Biotech	+1.32%	+2.89%	-4.73%	-9.35%	+77.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.65	Moderate Buy	$87.82	60.28% Upside
DYN Dyne Therapeutics	2.82	Moderate Buy	$33.07	98.75% Upside
IBRX ImmunityBio	2.86	Moderate Buy	$14.20	35.11% Upside
KRYS Krystal Biotech	3.00	Buy	$377.20	13.75% Upside

Current Analyst Ratings Breakdown

Latest DYN, BMRN, IBRX, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	IBRX ImmunityBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/30/2026	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$37.00
9/30/2026	DYN Dyne Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/30/2026	DYN Dyne Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
9/30/2026	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$38.00
9/30/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$50.00 ➝ $32.00
9/29/2026	DYN Dyne Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$47.00
9/25/2026	IBRX ImmunityBio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/24/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/24/2026	KRYS Krystal Biotech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$441.00
9/24/2026	KRYS Krystal Biotech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$441.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.29	$2.85 per share	19.24	$31.68 per share	1.73
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
IBRX ImmunityBio	$113.29M	98.32	N/A	N/A	($0.51) per share	-20.61
KRYS Krystal Biotech	$389.13M	25.22	$7.39 per share	44.90	$42.06 per share	7.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	148.08	10.11	0.39	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	41.56	36.20	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)

Latest DYN, BMRN, IBRX, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	DYN Dyne Therapeutics	-$0.9122	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	IBRX ImmunityBio	-$0.07	N/A	N/A	N/A	$59.23 million	N/A
11/2/2026	Q3 2026	KRYS Krystal Biotech	$1.86	N/A	N/A	N/A	$128.49 million	N/A
10/26/2026	Q3 2026	BMRN BioMarin Pharmaceutical	$1.35	N/A	N/A	N/A	$1.02 billion	N/A
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million
7/29/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
DYN Dyne Therapeutics	0.28	12.02	12.02
IBRX ImmunityBio	N/A	5.72	5.70
KRYS Krystal Biotech	N/A	8.32	7.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
DYN Dyne Therapeutics	96.68%
IBRX ImmunityBio	8.58%
KRYS Krystal Biotech	86.29%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
DYN Dyne Therapeutics	9.46%
IBRX ImmunityBio	66.10%
KRYS Krystal Biotech	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
DYN Dyne Therapeutics	258	186.75 million	169.08 million	Optionable
IBRX ImmunityBio	691	1.06 billion	359.28 million	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable

DYN, BMRN, IBRX, and KRYS Headlines

Recent News About These Companies

Why Krystal Biotech (KRYS) Is Drawing Fresh Attention

October 8 at 8:13 PM | uk.finance.yahoo.com

Krystal Biotech (KRYS) Stock Looks Overvalued After A 7x Run

October 8 at 8:13 PM | uk.finance.yahoo.com

Goldman starts coverage of Krystal Biotech stock at USD 441.00 target

October 8 at 8:13 PM | ad-hoc-news.deA

What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders

October 8 at 8:13 PM | finance.yahoo.com

Congress Asset Management Co. Increases Stock Holdings in Krystal Biotech, Inc. $KRYS

October 7 at 3:20 AM | marketbeat.com

Goldman Sachs sets USD 441 target for Krystal Biotech stock

October 6, 2026 | ad-hoc-news.deA

Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?

October 5, 2026 | insidermonkey.com

Krystal Biotech stock weighs Q2 growth against USD 441 target

October 4, 2026 | ad-hoc-news.deA

Goldman Sachs Resumes Coverage with a Buy Rating on Krystal Biotech (KRYS)

September 26, 2026 | theglobeandmail.com

The Goldman Sachs Group Upgrades Krystal Biotech (NASDAQ:KRYS) to Strong-Buy

September 25, 2026 | marketbeat.com

BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating

September 21, 2026 | marketscreener.comM

Bank of America Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price

September 21, 2026 | marketbeat.com

Bank of America Corp DE Invests $95.31 Million in Krystal Biotech, Inc. $KRYS

September 19, 2026 | marketbeat.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 18, 2026 | marketbeat.com

Corient Private Wealth LP Grows Stock Position in Krystal Biotech, Inc. $KRYS

September 17, 2026 | marketbeat.com

California State Teachers Retirement System Sells 2,494 Shares of Krystal Biotech, Inc. $KRYS

September 11, 2026 | marketbeat.com

Hsbc Holdings PLC Invests $3.65 Million in Krystal Biotech, Inc. $KRYS

September 11, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Holdings in Krystal Biotech, Inc. $KRYS

September 10, 2026 | marketbeat.com

Suma Krishnan Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

September 5, 2026 | insidertrades.com

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

September 3, 2026 | zacks.com

Krystal Biotech to Participate in 2026 Cantor Global Healthcare Conference

September 3, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DYN, BMRN, IBRX, and KRYS Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$54.79 -0.10 (-0.18%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$55.06 +0.27 (+0.50%)

As of 10/9/2026 07:54 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Dyne Therapeutics NASDAQ:DYN

$16.64 +0.27 (+1.65%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$16.53 -0.11 (-0.67%)

As of 10/9/2026 07:55 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

ImmunityBio NASDAQ:IBRX

$10.51 +0.60 (+6.05%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.61 +0.10 (+0.95%)

As of 10/9/2026 07:59 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Krystal Biotech NASDAQ:KRYS

$331.61 +4.31 (+1.32%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$327.07 -4.54 (-1.37%)

As of 10/9/2026 07:30 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYN, BMRN, IBRX, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYN, BMRN, IBRX, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYN, BMRN, IBRX, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DYN, BMRN, IBRX, and KRYS Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Dyne Therapeutics NASDAQ:DYN

ImmunityBio NASDAQ:IBRX

Krystal Biotech NASDAQ:KRYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYN, BMRN, IBRX, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYN, BMRN, IBRX, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYN, BMRN, IBRX, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DYN, BMRN, IBRX, and KRYS Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Dyne Therapeutics NASDAQ:DYN

ImmunityBio NASDAQ:IBRX

Krystal Biotech NASDAQ:KRYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools